$NHHS
NorthStar Healthcare Income, Inc. Stock $nhhs

$nhhs Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000150370721000021 Filed on May 14, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$57.33M	$72.89M
YoY Change	-21.34%	0.51%
Cost Of Revenue	$45.62M	$45.70M
YoY Change	-0.18%	1.07%
Gross Profit	$11.72M	$27.19M
YoY Change	-56.91%	-0.41%
Gross Profit Margin	20.43%	37.3%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$15.39M	$16.49M
YoY Change	-6.68%	-26.39%
% of Gross Profit	131.33%	60.64%
Operating Expenses
YoY Change
Operating Profit
YoY Change
Interest Expense	$16.03M	$16.68M
YoY Change	-3.92%	-4.12%
% of Operating Profit
Other Income/Expense, Net	$7.360M
YoY Change
Pretax Income	-$9.250M	-$11.54M
YoY Change	-19.84%	-37.42%
Income Tax	$15.00K	$14.00K
% Of Pretax Income
Net Earnings	-$10.16M	-$12.55M
YoY Change	-19.06%	-32.6%
Net Earnings / Revenue	-17.71%	-17.21%
Basic Earnings Per Share	-$0.05
Diluted Earnings Per Share	-$0.05
COMMON SHARES
Basic Shares Outstanding	190.6M shares	189.1M shares
Diluted Shares Outstanding	190.6M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$90.97M	$36.89M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$21.39M	$21.39M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$221.9M	$265.3M
YoY Change	-16.35%	1.91%
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$1.882B	$2.120B
YoY Change	-11.22%	-4.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities	$1.478B	$1.466B
YoY Change	0.86%	-2.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.313B	-$1.054B
YoY Change	24.62%	7.21%
Common Stock	$1.714B	$1.705B
YoY Change	0.57%	-0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.2M	$649.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.882B	$2.120B
YoY Change	-11.22%	-4.9%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$10.16M	-$12.55M
YoY Change	-19.06%	-32.6%
Depreciation, Depletion And Amortization	$15.39M	$16.49M
YoY Change	-6.68%	-26.39%
Cash From Operating Activities	-$6.660M	$2.429M
YoY Change	-374.19%	-220.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$903.0K
YoY Change	-100.0%	-265.08%
Cash From Investing Activities	$44.68M	-$1.265M
YoY Change	-3631.62%	-156.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$1.998M
YoY Change	-100.0%	1.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$20.34M	-$8.086M
YoY Change	151.58%	-41.01%
NET CHANGE
Cash From Operating Activities	-$6.660M	$2.429M
Cash From Investing Activities	$44.68M	-$1.265M
Cash From Financing Activities	-$20.34M	-$8.086M
Net Change In Cash	$17.67M	-$6.922M
YoY Change	-355.3%	-48.67%
FREE CASH FLOW
Cash From Operating Activities	-$6.660M	$2.429M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	NorthStar Healthcare Income, Inc.
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001503707
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	191266239	shares
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity File Number EntityFileNumber	000-55190
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	191266239	shares
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3663988
CY2021Q1	dei	City Area Code CityAreaCode	212
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	590 Madison Avenue, 34th Floor
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	547-2600
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90966000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65995000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	20276000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	27575000	USD
CY2021Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	1457397000	USD
CY2020Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	1483930000	USD
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	221944000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	229173000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	14735000	USD
CY2021Q1	us-gaap	Mortgage Loans On Real Estate Commercial And Consumer Net MortgageLoansOnRealEstateCommercialAndConsumerNet	36112000	USD
CY2020Q4	us-gaap	Mortgage Loans On Real Estate Commercial And Consumer Net MortgageLoansOnRealEstateCommercialAndConsumerNet	55864000	USD
CY2021Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	5000000	USD
CY2020Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	5000000	USD
CY2021Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	7277000	USD
CY2021Q1	nshi	Deferred Costs And Intangible Assets Net DeferredCostsAndIntangibleAssetsNet	26016000	USD
CY2020Q4	nshi	Deferred Costs And Intangible Assets Net DeferredCostsAndIntangibleAssetsNet	26483000	USD
CY2021Q1	us-gaap	Other Assets OtherAssets	17367000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	9681000	USD
CY2021Q1	us-gaap	Assets Assets	1882355000	USD
CY2020Q4	us-gaap	Assets Assets	1918436000	USD
CY2021Q1	us-gaap	Notes Payable NotesPayable	1397718000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	1416871000	USD
CY2021Q1	nshi	Line Of Credit Related Party LineOfCreditRelatedParty	35000000	USD
CY2020Q4	nshi	Line Of Credit Related Party LineOfCreditRelatedParty	35000000	USD
CY2021Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	3812000	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	8318000	USD
CY2021Q1	us-gaap	Advance Payments By Borrowers For Taxes And Insurance AdvancePaymentsByBorrowersForTaxesAndInsurance	4386000	USD
CY2020Q4	us-gaap	Advance Payments By Borrowers For Taxes And Insurance AdvancePaymentsByBorrowersForTaxesAndInsurance	3851000	USD
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	33632000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	38393000	USD
CY2021Q1	us-gaap	Other Liabilities OtherLiabilities	3938000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	3941000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	1478486000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1506374000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	191052014	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	191052014	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	190409341	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	190409341	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1910000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1904000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1712563000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1710023000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1313218000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1302755000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	467000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	401248000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	409639000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	2621000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	2423000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	403869000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	412062000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1882355000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1918436000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	28282000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32847000	USD
CY2021Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	29051000	USD
CY2020Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	39980000	USD
CY2021Q1	us-gaap	Other Operating Income OtherOperatingIncome	1000	USD
CY2020Q1	us-gaap	Other Operating Income OtherOperatingIncome	64000	USD
CY2021Q1	us-gaap	Revenues Revenues	57334000	USD
CY2020Q1	us-gaap	Revenues Revenues	72891000	USD
CY2021Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	2213000	USD
CY2020Q1	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	1905000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45618000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45701000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	16025000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	16679000	USD
CY2021Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	54000	USD
CY2020Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7000	USD
CY2021Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2769000	USD
CY2020Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	4431000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3033000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3029000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15387000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16489000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	786000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	83672000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	86336000	USD
CY2021Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7360000	USD
CY2020Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7515000	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9250000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11540000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-890000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-993000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-10155000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-12547000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	308000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-66000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10463000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12481000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	190630723	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	189038484	shares
CY2021Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-10155000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-12547000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-474000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1044000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-474000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1044000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10629000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13591000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	308000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-66000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10937000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13525000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	667504000	USD
CY2020Q1	nshi	Stock Redeemedor Called During Period Value Paymentof Advisor Asset Management Fees StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees	2500000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38000	USD
CY2020Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	86000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	85000	USD
CY2020Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	1998000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1044000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-12547000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	654454000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	412062000	USD
CY2021Q1	nshi	Stock Redeemedor Called During Period Value Paymentof Advisor Asset Management Fees StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees	2500000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46000	USD
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	240000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	350000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-474000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-10155000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	403869000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-10155000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-12547000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-890000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-993000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15387000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16489000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	786000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	784000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	766000	USD
CY2021Q1	us-gaap	Straight Line Rent StraightLineRent	-7639000	USD
CY2020Q1	us-gaap	Straight Line Rent StraightLineRent	-11000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	112000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	30000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	147000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	471000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	46000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	38000	USD
CY2021Q1	nshi	Paid In Kind Interest Added To Real Estate Debt Investment Loan Principal PaidInKindInterestAddedToRealEstateDebtInvestmentLoanPrincipal	105000	USD
CY2020Q1	nshi	Paid In Kind Interest Added To Real Estate Debt Investment Loan Principal PaidInKindInterestAddedToRealEstateDebtInvestmentLoanPrincipal	0	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7515000	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	653000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2021Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2500000	USD
CY2020Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2500000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	833000	USD
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	822000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7686000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1690000	USD
CY2021Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-4506000	USD
CY2020Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-749000	USD
CY2021Q1	nshi	Increase Decreasein Escrow Payable IncreaseDecreaseinEscrowPayable	535000	USD
CY2020Q1	nshi	Increase Decreasein Escrow Payable IncreaseDecreaseinEscrowPayable	26000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5336000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3217000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	221000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6660000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2429000	USD
CY2021Q1	nshi	Paymentsto Improve Real Estate PaymentstoImproveRealEstate	2416000	USD
CY2020Q1	nshi	Paymentsto Improve Real Estate PaymentstoImproveRealEstate	2127000	USD
CY2021Q1	nshi	Proceeds From Sale Of Real Estate Investing ProceedsFromSaleOfRealEstateInvesting	21258000	USD
CY2020Q1	nshi	Proceeds From Sale Of Real Estate Investing ProceedsFromSaleOfRealEstateInvesting	0	USD
CY2021Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	24878000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	0	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	USD
CY2020Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	859000	USD
CY2020Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	1765000	USD
CY2021Q1	nshi	Proceeds From Real Estate Debt Investment Modification Fee ProceedsFromRealEstateDebtInvestmentModificationFee	346000	USD
CY2020Q1	nshi	Proceeds From Real Estate Debt Investment Modification Fee ProceedsFromRealEstateDebtInvestmentModificationFee	0	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2020Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	903000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44675000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1265000	USD
CY2021Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	26000000	USD
CY2020Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2021Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	45722000	USD
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5942000	USD
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	362000	USD
CY2020Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	149000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	147000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1998000	USD
CY2021Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	240000	USD
CY2020Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	86000	USD
CY2021Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	350000	USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	0	employee
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2000000000.0	USD
CY2020Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	85000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-20343000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8086000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17672000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6922000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93570000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58820000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111242000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51898000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	575000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	943000	USD
CY2021Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2020Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	222000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Business and Organization<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), manages a diversified portfolio of investments in healthcare real estate, owned directly or through joint ventures, with a focus on the mid-acuity seniors housing sector, which the Company defines as assisted living (“ALF”), memory care (“MCF”), skilled nursing (“SNF”), independent living (“ILF”) facilities and continuing care retirement communities (“CCRC”), which have independent living, assisted living, skilled nursing and memory care available on one campus. Primarily through joint ventures, the Company is also invested in other healthcare property types, including medical office buildings (“MOB”), hospitals, rehabilitation facilities and ancillary healthcare services businesses. The Company’s investments are predominantly in the United States, but through its joint ventures also has international investments in the United Kingdom. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company conducts its operations so as to continue to qualify as a REIT for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC (the “Prior Advisor”) and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”), each an affiliate of the Company’s sponsor. The Prior Advisor invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which are collectively recorded as non-controlling interests on the accompanying consolidated balance sheets as of March 31, 2021 and December 31, 2020. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of March 31, 2021, the Company’s limited partnership interest in the Operating Partnership was 99.99%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is externally managed and has no employees. The Company is sponsored by Colony Capital, Inc. (NYSE: CLNY) (“Colony Capital” or the “Sponsor”), a leading global investment management firm. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colony Capital manages capital on behalf of its stockholders, as well as institutional and retail investors in private funds and non-traded and traded REITs. The Company’s advisor, CNI NSHC Advisors, LLC (the “Advisor”), is a subsidiary of Colony Capital and manages its day-to-day operations pursuant to an advisory agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2021, the Company raised total gross proceeds from the sale of shares of common stock totaling $2.0 billion (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The world continues to experience the broad effects of the coronavirus 2019 (“COVID-19”) pandemic, with efforts to address the pandemic impacting economic and financial markets globally and across all facets of industries, including real estate. The Company's healthcare real estate business and investments have experienced a myriad of challenges, including, but not limited to, declines in resident occupancy and operating cash flows, increases in cost burden faced by operators, lease concessions sought by tenants, and a stressed market affecting real estate values in general. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recovery from the impact of the COVID-19 pandemic on the Company’s operational and financial performance will depend on a variety of factors, which may differ considerably across regions and fluctuate over time. Recent guidance from state and local governments, including the easing of restrictions, the resumption of normal business operations in many municipalities, and lower reported infection rates are encouraging signs towards a recovery from the effects of the pandemic. Significant vaccine deployment and acceptance has begun to mitigate the number of confirmed COVID-19 cases, which in turn has helped to reduce preventative operating costs that continue to be incurred. However, occupancy challenges are still anticipated until such time that the rate of resident move-outs is outpaced by new resident admissions, for which the future trend remains uncertain. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates a recovery of its healthcare real estate business will span over future periods. An extended recovery period increases the risk of a prolonged negative impact on the Company’s financial condition and results of operations. While the Company has the ability to meet its near term liquidity needs, general market concerns over credit and liquidity continue and the effects of COVID-19 may also lead to heightened risk of litigation, with an ensuing increase in litigation and related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, the progression of the global economic recovery from the broad effects of COVID-19 remains difficult for the Company to assess and estimate the future impact of COVID-19 on the Company's results of operations. Accordingly, any estimates of the effects of COVID-19 as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q, and such estimates may change, the effects of which could be material. The Company will continue to monitor the progression of the economic recovery from COVID-19 and reassess its effects on the Company’s results of operations and recoverability of value across its assets as conditions change.</span></div>
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000.0	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000.0	shares
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	221900000	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	300000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of COVID-19 as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.</span></div>
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90966000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65995000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	20276000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	27575000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111242000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93570000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3400000	USD
CY2021Q1	nshi	Finance Lease Payments FinanceLeasePayments	200000	USD
CY2020Q1	nshi	Finance Lease Payments FinanceLeasePayments	200000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	498000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	576000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	155000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	59000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	17000	USD
CY2021Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	1149000	USD
CY2021Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.063
CY2021Q1	nshi	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	9000	USD
CY2021Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1314000	USD
CY2021Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	165000	USD
CY2021Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	nshi	Numberof Properties Heldfor Sale NumberofPropertiesHeldforSale	2	property
CY2021Q1	nshi	Numberof Properties Heldfor Sale NumberofPropertiesHeldforSale	2	property
CY2021Q1	us-gaap	Finite Lived Intangible Asset Acquired In Place Leases FiniteLivedIntangibleAssetAcquiredInPlaceLeases	4186000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Asset Acquired In Place Leases FiniteLivedIntangibleAssetAcquiredInPlaceLeases	4635000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	21387000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21387000	USD
CY2021Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	380000	USD
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	380000	USD
CY2021Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	25953000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	26402000	USD
CY2021Q1	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	63000	USD
CY2020Q4	us-gaap	Deferred Costs Leasing Net DeferredCostsLeasingNet	81000	USD
CY2021Q1	nshi	Deferred Costs And Intangible Assets Net DeferredCostsAndIntangibleAssetsNet	26016000	USD
CY2020Q4	nshi	Deferred Costs And Intangible Assets Net DeferredCostsAndIntangibleAssetsNet	26483000	USD
CY2020Q1	nshi	Amortizationof Deferred Costsand Intangible Assets AmortizationofDeferredCostsandIntangibleAssets	500000	USD
CY2021Q1	nshi	Amortizationof Deferred Costsand Intangible Assets AmortizationofDeferredCostsandIntangibleAssets	500000	USD
CY2021Q1	nshi	Deferred Costsand Finite Lived Intangible Assets Amortization Expense Remainderof Fiscal Year DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear	1403000	USD
CY2021Q1	nshi	Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year One DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearOne	593000	USD
CY2021Q1	nshi	Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Two DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	337000	USD
CY2021Q1	nshi	Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Three DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearThree	337000	USD
CY2021Q1	nshi	Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Four DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearFour	337000	USD
CY2021Q1	nshi	Deferred Costs And Finite Lived Intangible Assets Amortization Expense After Year Four DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1242000	USD
CY2021Q1	nshi	Deferred Costsand Finite Lived Intangible Assets Net DeferredCostsandFiniteLivedIntangibleAssetsNet	4249000	USD
CY2021Q1	nshi	Healthcare Facility Regulatory Reserve HealthcareFacilityRegulatoryReserve	6000000	USD
CY2021Q1	nshi	Ownership Interestin Condominiums OwnershipInterestinCondominiums	2327000	USD
CY2021Q1	nshi	Lessor Concession Granted Repayment Period Covid19 LessorConcessionGrantedRepaymentPeriodCOVID19	P12M
CY2020Q4	nshi	Ownership Interestin Condominiums OwnershipInterestinCondominiums	2327000	USD
CY2021Q1	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	5834000	USD
CY2020Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3798000	USD
CY2021Q1	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	2415000	USD
CY2020Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	2246000	USD
CY2021Q1	nshi	Utility Deposit Assets UtilityDepositAssets	513000	USD
CY2020Q4	nshi	Utility Deposit Assets UtilityDepositAssets	447000	USD
CY2021Q1	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	278000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous OtherAssetsMiscellaneous	863000	USD
CY2021Q1	us-gaap	Other Assets OtherAssets	17367000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	9681000	USD
CY2021Q1	nshi	Lease Terms Days Notice Required For Termination LeaseTermsDaysNoticeRequiredForTermination	30	D
CY2021Q1	nshi	Lease Terms Days Notice Required For Termination LeaseTermsDaysNoticeRequiredForTermination	30	D
CY2021Q1	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	3300000	USD
CY2020Q1	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	4200000	USD
CY2021Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7400000	USD
CY2021Q1	nshi	Lessor Concession Granted Period Covid19 LessorConcessionGrantedPeriodCOVID19	P90D
CY2021Q1	nshi	Lessor Concession Granted Payments Deferred Covid19 LessorConcessionGrantedPaymentsDeferredCOVID19	1200000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	800000	USD
CY2021Q1	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	USD
CY2021Q1	nshi	Acquisition Feeand Expense Cap AcquisitionFeeandExpenseCap	0.060
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	21900000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021Q1	us-gaap	Land Land	230406000	USD
CY2020Q4	us-gaap	Land Land	234706000	USD
CY2021Q1	us-gaap	Land Improvements LandImprovements	23215000	USD
CY2020Q4	us-gaap	Land Improvements LandImprovements	23797000	USD
CY2021Q1	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	1376487000	USD
CY2020Q4	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	1389706000	USD
CY2021Q1	us-gaap	Tenant Improvements TenantImprovements	16523000	USD
CY2020Q4	us-gaap	Tenant Improvements TenantImprovements	16172000	USD
CY2021Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2587000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2535000	USD
CY2021Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	106673000	USD
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	108055000	USD
CY2021Q1	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	1755891000	USD
CY2020Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	1774971000	USD
CY2021Q1	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	298494000	USD
CY2020Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	291041000	USD
CY2021Q1	us-gaap	Real Estate Investments RealEstateInvestments	1457397000	USD
CY2020Q4	us-gaap	Real Estate Investments RealEstateInvestments	1483930000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	14900000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	16000000.0	USD
CY2021Q1	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	800000	USD
CY2020Q1	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2021Q1	us-gaap	Equity Method Investments EquityMethodInvestments	221944000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	229173000	USD
CY2019Q2	nshi	Equity Method Investment Numberof Facilities Sold EquityMethodInvestmentNumberofFacilitiesSold	11	facility
CY2019Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	118000000.0	USD
CY2019Q1	nshi	Proceeds From Sale Of Property Held For Sale Net ProceedsFromSaleOfPropertyHeldForSaleNet	4300000	USD
CY2021Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	300000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-890000	USD
CY2021Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	859000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-993000	USD
CY2020Q1	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	1765000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	33973000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	467008000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	19696000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20406000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	670302000	USD
CY2021Q1	nshi	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	204276000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	1415661000	USD
CY2021Q1	nshi	Debt Instrument Principal Deferred Covid19 DebtInstrumentPrincipalDeferredCOVID19	1300000000	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	8318000	USD
CY2021Q1	nshi	Related Party Transaction Dueto Related Parties Amount Incurred RelatedPartyTransactionDuetoRelatedPartiesAmountIncurred	5658000	USD
CY2021Q1	nshi	Related Party Transaction Dueto Related Parties Amount Paid RelatedPartyTransactionDuetoRelatedPartiesAmountPaid	10164000	USD
CY2021Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	3812000	USD
CY2021Q1	nshi	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Shares Issuedas Paymentfor Asset Management Fees NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationSharesIssuedasPaymentforAssetManagementFees	2500000	USD
CY2021Q1	nshi	Stock Redeemedor Called During Period Shares Paymentof Advisor Asset Management Fees StockRedeemedorCalledDuringPeriodSharesPaymentofAdvisorAssetManagementFees	600000	shares
CY2021Q1	nshi	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Shares Issuedas Paymentfor Asset Management Fees NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationSharesIssuedasPaymentforAssetManagementFees	2500000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45625	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38125	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	147625	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	193250	USD
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	86000000.0	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	300000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-100000	USD
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	5	segment
CY2021Q1	nshi	Rentaland Resident Fee Income RentalandResidentFeeIncome	57334000	USD
CY2021Q1	us-gaap	Interest Income Operating InterestIncomeOperating	2213000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45618000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	16025000	USD
CY2021Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	54000	USD
CY2021Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2769000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3033000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15387000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	786000	USD
CY2021Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	7360000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	7515000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-890000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-10155000	USD
CY2020Q1	nshi	Rentaland Resident Fee Income RentalandResidentFeeIncome	72891000	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	1905000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45701000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	16679000	USD
CY2020Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7000	USD
CY2020Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	4431000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3029000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16489000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2020Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-993000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-12547000	USD
CY2021Q1	us-gaap	Assets Assets	1882355000	USD
CY2020Q4	us-gaap	Assets Assets	1918436000	USD
CY2021Q1	us-gaap	Number Of Real Estate Properties NumberOfRealEstateProperties	72	property
CY2021Q1	us-gaap	Number Of Units In Real Estate Property NumberOfUnitsInRealEstateProperty	10181	unit
CY2021Q1	us-gaap	Noninterest Income NoninterestIncome	57334000	USD

Files In Submission

Name	View Source	Status
0001503707-21-000021-index-headers.html	Edgar Link	pending
0001503707-21-000021-index.html	Edgar Link	pending
0001503707-21-000021.txt	Edgar Link	pending
0001503707-21-000021-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nshi-20210331.htm	Edgar Link	pending
nshi-20210331.xsd	Edgar Link	pending
nshi-20210331_cal.xml	Edgar Link	unprocessable
nshi-20210331_def.xml	Edgar Link	unprocessable
nshi-20210331_g1.jpg	Edgar Link	pending
nshi-20210331_g2.jpg	Edgar Link	pending
nshi-20210331_htm.xml	Edgar Link	completed
nshi-20210331_lab.xml	Edgar Link	unprocessable
nshi-20210331_pre.xml	Edgar Link	unprocessable
nshi03312021exhibit101.htm	Edgar Link	pending
nshi03312021exhibit311.htm	Edgar Link	pending
nshi03312021exhibit312.htm	Edgar Link	pending
nshi03312021exhibit321.htm	Edgar Link	pending
nshi03312021exhibit322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NHHS
NorthStar Healthcare Income, Inc. Stock $nhhs

2021 Q1 Form 10-Q Financial Statement

#000150370721000021 Filed on May 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHHS NorthStar Healthcare Income, Inc. Stock $nhhs

2021 Q1 Form 10-Q Financial Statement

#000150370721000021 Filed on May 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHHS
NorthStar Healthcare Income, Inc. Stock $nhhs